Blood tests are also used to monitor thyroid cancers. Medullary thyroid cancer accounts for around 5% of all thyroid cancer cases and is categorized into two types: sporadic (not inherited) and ...

[131] Several drugs have been synthesized in the past few years based on advances in our understanding of the molecular mechanisms underlying the pathophysiology of thyroid cancers. However ...

Eli Lilly and Company received FDA approval for selpercatinib (Retevmo) in September 2024, a notable development for treating advanced or metastatic medullary thyroid cancer (MTC) with RET mutations.